Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MabSpace Starts US Trial of PD-L1 Drug; China Trial to Begin Soon

publication date: Apr 13, 2018

MabSpace Biosciences of Suzhou has dosed the first patient in a US Phase I trial of MSB2311, its second generation PD-L1 treatment for advanced solid tumors. It is the first MabSpace molecule to begin clinical trials. In China, MSB2311 is in the late stages of the CFDA review process, and MabSpace expects it will start a China Phase I trial soon. Using its proprietary platform MabSpace provides discovery services to other biopharmas and is also developing its own portfolio of six immuno-oncology antibodies, which are designed to work in combination with MSB2311. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital